

## COVID UPDATE

We continue to keep all of our shareholders and their families in our thoughts as we adapt to life during a pandemic. Here at the Infrasonix facility we are in the midst of the 2<sup>nd</sup> phase of the Georgia state resumption of activities in the workplace, and as we enter phase three, we look forward to a safe and healthy summer.

## In house activities.

As mentioned in our April update, we are fortunate in our ability to conduct a great deal of research work remotely. To this end, we have been able to set up several teams that are working in tandem to not only keep us moving forward, but to accelerate our research efforts. We have learned from our success in obtaining intellectual property protection around the world that we are indeed becoming the leaders in bioacoustic research within the world of infrasound.

We are often asked if we could give a simple, easy to understand visual of the Infrasound technology. Some of us who are not doctors or scientists would like to explain infrasound to friends and family. The following is a statement that may help.

*“A vast new trove of valuable medical information has been revealed for the first time by the INFRASONIX technology -confirming that the human body is a massive source of naturally emitted infrasound”.*

## INTELLECTUAL PROPERTY




Infrasonix International Patent filed in 44 countries and territories as indicated in red on the map.

Two patents.

1. Technology patent filed in USA with extensive additional trade secret protection.
2. Application patent filed internationally.
3. Significant additional IP filings planned for 2020.

The graph below is a great representation of the impact the detection of infrasound will have in the future of medical diagnosis.



You may also recall from previous accounts, as illustrated in this diagram, that when our sensors were placed on the chest in proximity to the human heart, it was discovered that 80% of the sound coming from this area appeared in the Infrasound range. This implies that for 200 years, general practitioners and cardiovascular surgeons have been able to hear only 20% of the sound emitted by the human heart.

**John Mitchell,**  
CTO



Infrasonix - Chief Technology Officer John Mitchell has not slowed down during the past several months. He has successfully managed an internationally renowned team of scientists that he has put together during this time.

As a brief introduction to this team we felt it important to put names to this hard-working group and in future updates we will feature more comprehensive bios on our team members. It is our desire that these bios will enable you to understand the depth of talent and experience that is working to move our technology forward.

The sensor pictured here is an early version within a custom housing. We are currently working with several second generation sensors.

## THE TEAM

**Randy Bachtel, P.E.** In Vitro Team Lead. 30+ years Machine Design, Mechanical engineering, and 3D CAD design; Advanced product design experience with FEA Tools, Design of Experiments, Reliability Engineering and Manufacturing processes.

**Ken Cohen, Ph.D.** In Vivo Team Lead. Physiologist and Biomedical Engineer, Biomedical Engineering and Research Laboratory NASA-Kennedy Space Center. 15+ years' experience studying environmental stressors on physiology. Human subject testing, cardiovascular physiology, countermeasures to environmental stressors, medical devices, and physiological monitoring.

**Mark Johnson, P.E.** Sensors & Arrays Team Lead. A design engineer with 37 years in the field of complex electronic systems & products with globally recognized industry leaders.

**Amirtaha Taebi, Ph.D.** Signal Processing Team Lead. An expert in developing systems and advanced signal processing methodologies to monitor heart sounds & vibrations.

**Fardin Khalili Ph.D.** Team Leader In-Silico Modelling. A leader in multi-physics computational modeling of human hemodynamics. Areas of focus include stenotic artery; shear-thickening fluids & mechanical heart valves.

## INFRASONIX – Proprietary Biosensor



*This is an early large version of the sensor in a traditional housing which has not been optimized for size or weight.*

- *Longitudinal Measurement – providing early disease state monitoring for preventative care.*
- *The information detected for the first time as it emerges from the human body allows us to diagnose a plethora of disease states currently undetectable within the human body.*